DXCM:NSD-DexCom Inc (USD)

COMMON STOCK | Medical Devices |

Last Closing

USD 80.24

Change

+0.70 (+0.88)%

Market Cap

USD 30.74B

Volume

1.15M

Analyst Target

USD 475.06
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-12-24 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap
PODD Insulet Corporation

-0.10 (-0.04%)

USD 19.01B
MASI Masimo Corporation

+0.80 (+0.48%)

USD 9.43B
BRKR Bruker Corporation

+0.86 (+1.50%)

USD 9.04B
PRCT Procept Biorobotics Corp

+2.57 (+3.17%)

USD 4.83B
NVCR Novocure Ltd

+0.48 (+1.57%)

USD 3.61B
NARI Inari Medical Inc

+0.41 (+0.77%)

USD 3.25B
LIVN LivaNova PLC

-0.24 (-0.51%)

USD 2.83B
IRTC iRhythm Technologies Inc

+0.71 (+0.80%)

USD 2.67B
QDEL Quidel Corporation

-0.08 (-0.18%)

USD 2.57B
TMDX TransMedics Group Inc

+1.25 (+2.00%)

USD 2.07B

ETFs Containing DXCM

CYBG:LSE VanEck Bionic Engineering.. 9.88 % 0.00 %

+0.12 (+1.11%)

N/A
EKG First Trust Nasdaq Lux Di.. 8.50 % 0.00 %

+0.09 (+1.11%)

USD 2.66M
CIB0:XETRA VanEck Bionic Engineering.. 8.23 % 0.00 %

N/A

USD 4.87M
EDOC:AU BetaShares Digital Health.. 7.25 % 0.00 %

N/A

N/A
CURG:LSE VanEck Genomics and Healt.. 6.80 % 0.00 %

+0.08 (+1.11%)

USD 5.35M
SANE 6.79 % 0.00 %

N/A

N/A
CURE:XETRA VanEck Genomics and Healt.. 6.37 % 0.00 %

N/A

N/A
FDHT Fidelity Covington Trust .. 5.12 % 0.00 %

+0.06 (+1.11%)

USD 8.46M
FDOC:LSE Fidelity Digital Health U.. 5.04 % 0.00 %

+0.04 (+1.11%)

USD 3.18M
W311:XETRA HAN-GINS Indxx Healthcare.. 4.67 % 0.00 %

N/A

USD 0.02B
WELL:PA HAN-GINS Indxx Healthcare.. 4.67 % 0.00 %

+0.06 (+1.11%)

N/A
WELL:SW HAN-GINS Indxx Healthcare.. 4.67 % 0.00 %

N/A

N/A
DIP 4.61 % 0.00 %

N/A

N/A
FDHT:XETRA Fidelity Digital Health U.. 4.55 % 0.00 %

N/A

N/A
MEDI Harbor Health Care ETF 4.19 % 0.00 %

-0.08 (1.11%)

USD 0.02B
EDOC:LSE Global X Telemedicine & D.. 4.14 % 0.00 %

+0.07 (+1.11%)

USD 2.08M
EDOG:LSE Global X Telemedicine & D.. 4.14 % 0.00 %

+0.04 (+1.11%)

USD 0.42M
DDOC:F Global X Telemedicine & D.. 4.07 % 0.00 %

N/A

USD 4.62M
UMDV:SW iShares US Medical Device.. 4.00 % 0.00 %

N/A

N/A
SN5R:XETRA Global X Internet of Thin.. 3.93 % 0.00 %

N/A

USD 3.06M
SNSR:SW Global X Internet of Thin.. 3.93 % 0.00 %

N/A

USD 2.52M
SNSG:LSE Global X Internet of Thin.. 3.93 % 0.00 %

+0.02 (+1.11%)

USD 2.50M
HLTH:AU VanEck Global Healthcare .. 2.36 % 0.00 %

+0.06 (+1.11%)

USD 0.06B
RSPH Invesco S&P 500 Equal Wei.. 1.90 % 0.00 %

+0.14 (+1.11%)

USD 0.88B
BFIT 0.00 % 0.50 %

N/A

N/A
IHI iShares U.S. Medical Devi.. 0.00 % 0.43 %

+0.43 (+1.11%)

N/A
LNGR 0.00 % 0.50 %

N/A

N/A
GDNA 0.00 % 0.00 %

N/A

N/A
SLIM 0.00 % 0.50 %

N/A

N/A
SNSR Global X Internet of Thin.. 0.00 % 0.69 %

+0.26 (+1.11%)

USD 0.24B
DBPD:F Xtrackers - ShortDAX x2 D.. 0.00 % 0.00 %

N/A

N/A
EDOC Global X Telemedicine & D.. 0.00 % 0.00 %

+0.03 (+1.11%)

USD 0.04B
DDOC:XETRA Global X Telemedicine & D.. 0.00 % 0.00 %

N/A

USD 5.39M
IMCG iShares Morningstar Mid-C.. 0.00 % 0.00 %

+0.70 (+1.11%)

N/A
W311:F HAN-GINS Indxx Healthcare.. 0.00 % 0.00 %

N/A

USD 0.02B
CVGB:LSE 0.00 % 0.00 %

N/A

N/A
CAVE:LSE 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Medical Devices) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -35.34% 43% F 25% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -35.34% 43% F 24% F
Trailing 12 Months  
Capital Gain -35.05% 43% F 25% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -35.05% 43% F 24% F
Trailing 5 Years  
Capital Gain 49.06% 89% A- 74% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 49.06% 89% A- 71% C-
Average Annual (5 Year Horizon)  
Capital Gain 7.07% 48% F 56% F
Dividend Return 7.07% 48% F 53% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 35.60% 81% B- 53% F
Risk Adjusted Return 19.86% 73% C 53% F
Market Capitalization 30.74B 100% F 97% N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.